TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2876772
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (C. parvum) administered intrapleurally and intravenously (7 mg injected into the pleural space and 7 mg intravenously once between days 6 and 12 postoperatively, followed by 7 mg intravenously every 3rd month during the 1st year)
Study: 2876772
Drug: Placebo (intrapleural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intrapleural administration of 35 cc of saline)
Study: 30661702
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (50000 IU weekly for 9 weeks)
Study: 29282609
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum (5 × 10^7 cfu g−1)
Study: 29282609
Drug: Lactobacillus bulgaricus
Normalized name: Lactobacillus bulgaricus
DrugBank: Lactobacillus delbrueckii bulgaricus (DB16540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus bulgaricus (5 × 10^7 cfu g−1)
Study: 29282609
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei (5 × 10^7 cfu g−1)
Study: 25378426
Drug: TMSsyn group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMSsyn group (synchronous picture-naming training with contralesional 1 Hz-rTMS for 10 daily sessions)
Study: 25378426
Drug: TMSsham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMSsham group (concurrent naming task with sham 1 Hz-rTMS)
Study: 15321258
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg diamorphine
Study: 8476582
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg once daily for 7-14 days
Study: 8476582
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg twice daily for 7-14 days
Study: 23221579
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DHA and 300 mg EPA supplementation for 6 months
Study: 23221579
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL olive oil/d for 6 months (Control)
Study: 21722960
Drug: Cyanocobalamin formulated
Normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyanocobalamin formulated with 100-mg SNAC (5 mg dose)
Study: 21722960
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available 5-mg cyanocobalamin tablet
Study: 21722960
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available 1-mg cyanocobalamin IV
Study: 19303160
Drug: PI-88 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-88 (160 mg/day)
Study: 19303160
Drug: PI-88 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-88 (250 mg/day)
Study: 17040264
Drug: Hydrocortisone butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone butyrate ointment 1%
Study: 10931801
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose on day 1, followed by 75 mg/d) plus aspirin (325 mg/d)
Study: 10931801
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d) plus aspirin (325 mg/d)
Study: 10931801
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg BID) plus aspirin (325 mg/d)
Study: 10931801
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Clopidogrel and Ticlopidine)
Study: 7963711
Drug: sCD4‐PE40, 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCD4‐PE40, 1, 5, 10, or 15 micrograms/kg by intravenous bolus once a month for 2 months, then weekly for 6 weeks.
Study: 7963711
Drug: sCD4‐PE40, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCD4‐PE40, 10 micrograms/kg (maximally tolerated dose).
Study: 30396343
Drug: Moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion therapy with educational video program
Study: 28205278
Drug: 1.25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 μg ramosetron
Study: 28205278
Drug: 2.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg ramosetron
Study: 28205278
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg ramosetron
Study: 18204339
Drug: Pindolol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 7.5 mg/d
Study: 8126146
Drug: Nal-Glu +
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal-Glu + T 50 mg
Study: 8126146
Drug: Nal-Glu +
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal-Glu + T 100 mg
Study: 8126146
Drug: Nal-Glu +
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal-Glu + T + Teslac 250 mg
Study: 2577498
Drug: High-dose ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ranitidine (300 mg q.d.s.)
Study: 2577498
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose ranitidine (300 mg nocte)
Study: 2577498
Drug: Standard ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ranitidine therapy
Study: 175669
Drug: Split-course radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split-course radiation therapy
Study: 175669
Drug: Continuous radiation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous radiation therapy
Study: 27771761
Drug: Coping skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping skills training for junior gynecologists (12 weekly sessions over 3 months)
Study: 19382463
Drug: Tanreqing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanreqing Injection (20 mL) with 5% G/NS (500 mL) once a day for two weeks
Study: 19382463
Drug: Yanhuning injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yanhuning injection (0.4 g) with 5% G/NS (500 mL) once a day for two weeks
Study: 11952025
Drug: Enteric-coated fluoxetine
Normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated fluoxetine 90 mg on both days (LPWDx2)
Study: 11952025
Drug: Placebo 14
Normalized name: Ascorbic Acid/Calcium Ascorbate/Calcium Threonate/Cyanocobalamin/Folic Acid/Iron/Succinic Acid;Placebo 140 MG-60 MG-0.8 MG-0.01 MG-1 MG-151 MG-150 MG; NA Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 14 days before menses and enteric-coated fluoxetine 90 mg 7 days before menses (LPWDx1)
Study: 1771220
Drug: Glucose 0
Normalized name: glucose 0.4 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 0 g (Control)
Study: 1771220
Drug: Glucose 30
Normalized name: glucose 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 30 g
Study: 1771220
Drug: Glucose 100
Normalized name: glucose 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 100 g
Study: 6941444
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g (single oral dose, pre-operatively)
Study: 1496226
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy following lumpectomy
Study: 1496226
Drug: No radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No radiation therapy following lumpectomy
Study: 1496226
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy following IBTR
Study: 6196251
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (10 patients)
Study: 26882332
Drug: Behavioral parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral parent training (8 group sessions) and brief teacher consultation to establish a Daily Report Card
Study: 26882332
Drug: Extended‐release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended‐release methylphenidate (equivalent to .15 mg/kg/dose bid)
Study: 25030943
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg intramuscularly immediately after ERCP
Study: 12598340
Drug: S16020 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S16020 (80 or 100 mg/m2, 3‐h infusion every 3 weeks)
Study: 12598340
Drug: Methotrexate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (40 or 50 mg/m2, bolus injection weekly for a minimum of 6 weeks)
Study: 8739138
Drug: Local antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antifungal agent (miconazole, 2% gel) for 4 weeks
Study: 8739138
Drug: Systemic antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antifungal agent (fluconazole, 50 mg) for 2 weeks
Study: 25283470
Drug: Milnacipran (serotonin-norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (serotonin-norepinephrine reuptake inhibitor)
Study: 23392399
Drug: ICAM-1 (intercellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICAM-1 (intercellular adhesion molecule 1)
Study: 23392399
Drug: VCAM-1 (vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCAM-1 (vascular cell adhesion molecule 1)
Study: 23392399
Drug: TNF-α receptor
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-α receptor 1 (tumor necrosis factor α receptor 1)
Study: 20927577
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) group
Study: 18171181
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hand gel)
Study: 17139600
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with inhaled iloprost and bosentan
Study: 17139600
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with inhaled iloprost and sildenafil
Study: 17139600
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with bosentan and sildenafil
Study: 17139600
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with two or three of the mentioned drugs
Study: 11070991
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of somatostatin analogues
Study: 11070991
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (e.g., bromocriptine)
Study: 8865083
Drug: Control clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control clamp (CC)
Study: 6861871
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine tablets (20-40 mg every 4 to 6 hours)
Study: 6861871
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine solution (20-40 mg every 4 to 6 hours)
Study: 30501629
Drug: In-clinic physical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic physical therapy focused on strengthening
Study: 30501629
Drug: In-clinic physical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic physical therapy containing placebo
Study: 26770048
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (group D)
Study: 25264782
Drug: Biojector IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biojector IM injection of rAd5 vaccine at 10^10 PU
Study: 25264782
Drug: Needle injection
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle injection of rAd5 vaccine at 10^10 PU
Study: 25264782
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of rAd5 vaccine
Study: 25264782
Drug: Biojector delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biojector delivery of rAd5 vaccine
Study: 22419732
Drug: Alogliptin 12.5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg plus pioglitazone (any dose)
Study: 22419732
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg plus pioglitazone (any dose)
Study: 2392794
Drug: Transcricoid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcricoid injection of 100 mg lignocaine
Study: 2392794
Drug: Spray as
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray as you go technique with 240 mg lignocaine
Study: 373777
Drug: Ambroxol 45
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 45 mg/d
Study: 373777
Drug: Bromhexine 36
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine 36 mg/d
Study: 27726423
Drug: Intralesional steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroids (8 mg of dexamethasone plus 2 mL of lidocaine)
Study: 27726423
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (3 mL of PRP activated with 0.45 mL of 10% calcium gluconate)
Study: 1535020
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate depot 3.75 mg injected every 24 days
Study: 1535020
Drug: Danazol 600-800
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600-800 mg daily
Study: 31743424
Drug: Optimal individualized
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal individualized treatment regime (ITR) using data from a 2 × 2 crossover study
Study: 20609226
Drug: Sequential medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential medium (group A)
Study: 18711172
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) 4 mg intravenously every 3 months for 1 year
Study: 14962261
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with etoposide 80 mg/m² and thioguanine 100 mg/m² twice daily on 5 days and idarubicin 15 mg/m² on 3 days (ETI)
Study: 14962261
Drug: Intravenous combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous combination of cytarabine 100 mg/m² twice daily on 5 days, idarubicin 12 mg/m² x 1, and thioguanine (TAI)
Study: 11422429
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (12 U) injected into the carpal tunnel weekly for 7 weeks
Study: 11422429
Drug: Placebo injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected into the carpal tunnel weekly for 7 weeks
Study: 9422907
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia administered before tooth removal
Study: 9422907
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia administered after tooth removal
Study: 8387410
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of tetravalent reassortant rhesus rotavirus vaccine (4 x 10(4) PFU)
Study: 8387410
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of tetravalent reassortant rhesus rotavirus vaccine (4 x 10(5) PFU)
Study: 8387410
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of tetravalent reassortant rhesus rotavirus vaccine
Study: 8387410
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of tetravalent reassortant rhesus rotavirus vaccine
Study: 29933718
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg per day for 12 weeks)
Study: 29933718
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg cellulose acetate per day for 12 weeks)
Study: 27733521
Drug: High-amylose maize
Normalized name: hydroxypropyl distarch phosphate, high amylose corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-amylose maize resistant starch type 2 (HAM-RS2) bagel (25 g/d)
Study: 20804058
Drug: Hypotensive anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive anesthesia (induced by speeding up propofol injection and maintaining general anesthesia at 4.4-9 mg/kg x hr)
Study: 14723093
Drug: Evra patch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evra patch, worn for 7 days
Study: 14723093
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (COCs), taken daily
Study: 11010941
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Fe/d as ferrous sulfate for 12 weeks
Study: 8772471
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hydrocortisone (oral administration)
Study: 8772471
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms of corticotropin-releasing hormone (intravenous administration)
Study: 6229735
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg/day)
Study: 29992869
Drug: Treatment (home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (home visiting program 'Pro Kind')
Study: 22814850
Drug: LiRIS 200
Normalized name: IRIS TENAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiRIS 200 mg
Study: 22814850
Drug: LiRIS 650
Normalized name: IRIS TENAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiRIS 650 mg
Study: 22814850
Drug: LiRIS 200
Normalized name: IRIS TENAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiRIS 200 mg and 650 mg
Study: 20632059
Drug: Topical 0.4%
Normalized name: fluoride topical 0.4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.4% glyceryl trinitrate (GTN) treatment for 40 days
Study: 20632059
Drug: Topical 0.4%
Normalized name: fluoride topical 0.4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.4% glyceryl trinitrate (GTN) treatment for 80 days
Study: 20632059
Drug: Topical 0.4%
Normalized name: fluoride topical 0.4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.4% glyceryl trinitrate (GTN) treatment (both groups)
Study: 17846259
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (sertraline, 50-200 mg daily)
Study: 11476360
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (HR)
Study: 9836002
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (low dosage)
Study: 9836002
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (high pharmacologic dosage)
Study: 2971504
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dose of depot‐medroxyprogesterone acetate (DMPA)
Study: 2971504
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg dose of depot‐medroxyprogesterone acetate (DMPA)
Study: 23541417
Drug: CC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC and rFSH (group B)
Study: 23541417
Drug: CC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC and hMG (group A)
Study: 20668943
Drug: Phenylalanine (Phe)
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylalanine (Phe) loading test (100 mg/kg)
Study: 18840367
Drug: Amlodipine/Ramipril combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Ramipril combination therapy (mean dose 7.60/7.60 mg)
Study: 18840367
Drug: Amlodipine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine monotherapy (mean dose 7.97 mg)
Study: 18840367
Drug: Amlodipine/Ramipril combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Ramipril combination therapy
Study: 16880243
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg) administered via a 15-minute infusion every 3 or 4 weeks for 12 infusions
Study: 12818279
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg NT‐3 three times per week (TTW)
Study: 15612515
Drug: Glimepiride (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (up to 4 mg)
Study: 15612515
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (4 mg glimepiride plus 2 g metformin)
Study: 9971866
Drug: Thyroxine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine alone (usual dose)
Study: 25816110
Drug: High-dose Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Losartan (High-Los)
Study: 15517668
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin chloride 10 mg (qd)